Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas

Journal of Clinical Oncology

Volumn 23, Issue 30, 2005, Pages 7565-7573

  Fisher, Richard I ^a   Kaminski, Mark S ^a   Wahl, Richard L ^a   Knox, Susan J ^a   Zelenetz, Andrew D ^a   Vose, Julie M ^a   Leonard, John P ^a   Kroll, Stewart ^a   Goldsmith, Stanley J ^a   Coleman, Morton ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTHRAQUINONE; ANTINEOPLASTIC AGENT; TOSITUMOMAB; TOSITUMOMAB I 131; IODINE 131 ANTI B1 ANTIBODY; IODINE-131 ANTI-B1 ANTIBODY; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE;

ARTICLE; BONE MARROW; CANCER GROWTH; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; FOLLOW UP; HISTOLOGY; HUMAN; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; ADULT; AGED; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; FOLLICULAR LYMPHOMA; IMMUNOLOGY; MALE; MANTLE CELL LYMPHOMA; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REMISSION; SALVAGE THERAPY; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IODINE RADIOISOTOPES; LYMPHOMA, FOLLICULAR; LYMPHOMA, LOW-GRADE; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOIMMUNOTHERAPY; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL RATE;

EID: 32944476224     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.00.9217     Document Type: Article

References (32)

1. Gallagher CJ, Gregory WM, Jones AE, et al: Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 4:1470-1480, 1986
2. Fisher RI: Overview of non-Hodgkin's lymphoma: Biology, staging, and treatment. Semin Oncol 30:3-9, 2003
3. Horning SJ: Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20:75-88, 1993
4. Fisher R, LeBlanc M, Press OW, et al: New treatment options have changed the natural history of follicular lymphoma. Blood 104:168a, 2004 (abstr 168)
5. Johnson PW, Rohatiner AZ, Whelan JS, et al: Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center. J Clin Oncol 13:140-147, 1995
6. Bierman PJ, Vose JM, Anderson JR, et al: High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 15:445-450, 1997
7. Acker B, Hoppe RT, Colby TV, et al: Histologic conversion in the non-Hodgkin's lymphomas. J Clin Oncol 1:11-16, 1983
8. Bastion Y, Sebban C, Berger F, et al: Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 15:1587-1594, 1997
9. Davis TA, Kaminski MS, Leonard JP, et al: The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 10:7792-7798, 2004
10. Witzig TE, Flinn IW, Gordon LI, et al: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20:3262-3269, 2002
11. Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463, 2002
12. Nourigat C, Badger CC, Bernstein ID: Treatment of lymphoma with radiolabeled antibody: Elimination of tumor cells lacking target antigen. J Natl Cancer Inst 82:47-50, 1990
13. Kaminski MS, Zasadny KR, Francis IR, et al: Radioimmunotherapy of B-cell lymphoma with [131 I] anti-B1 (Anti-CD20) antibody. N Engl J Med 329:459-465, 1993
14. Kaminski MS, Zasadny KR, Francis IR, et al: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14:1974-1981, 1996
15. Kaminski MS, Zelenetz AD, Press OW, et al: Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19:3918-3928, 2001
16. Vose JM, Wahl RL, Saleh M, et al: Multicenter phase II study of Iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 18:1316-1323, 2000
17. Horning SJ, Younes A, Jain V, et al: Efficacy and safety of tositumomab and Iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 23:712-719, 2005
18. Wahl RL, Kroll S, Zasadny KR: Patient-specific whole-body dosimetry: Principles and a simplified method for clinical implementation. J Nucl Med 39:14S-20S, 1998
19. Kaminski MS, Estes J, Zasadny KR, et al: Radioimmunotherapy with iodine 131 tositumomab for relapsed or refractory B-cell non-Hodgkin's lymphoma: Updated results and long-term follow-up of the University of Michigan experience. Blood 96:1259-1266, 2000
20. Davies AJ, Rohatiner AZ, Howell S, et al: Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 22:1469-1479, 2004
21. The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 49:2112-2135, 1982
22. Zelenetz AD, Saleh M, Vose J, et al: Patients with transformed low grade lymphoma attain durable responses following outpatient radioimmunotherapy with tositumomab and iodine I 131 tositumomab (Bexxar). Blood 100: 357a, 2002 (abstr 1384)
23. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-cd20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
24. Stashenko P, Nadler LM, Hardy R, et al: Characterization of a human B lymphocyte-specific antigen. J Immunol 125:1678-1685, 1980
25. Anderson KC, Bates MP, Slaughenhoupt BL, et al: Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood 63:1424-1433, 1984
26. Press OW, Howell-Clark J, Anderson S, et al: Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 83: 1390-1397, 1994
27. Tedder TF, Forsgren A, Boyd AW, et al: Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes. Eur J Immunol 16:881-887, 1986
28. Shan D, Ledbetter JA, Press OW: Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91: 1644-1652, 1998
29. Bennett JM, Kaminski MS, Leonard JP, et al: Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine 1131 tositumomab. Blood 105:4576-4582, 2005
30. Schouten HC, Bierman PJ, Vaughan WP, et al: Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation. Blood 74:2579-2584, 1989
31. Freedman AS, Ritz J, Neuberg D, et al: Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. Blood 77:2524-2529, 1991
32. Wiseman GA, Witzig TE: Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm 20:185-188, 2005